India's weight-loss medication market poised for transformation as Novo Nordisk patent expires, paving way for affordable alternatives

The expiration of Novo Nordisk's patent on weight-loss medications in India marks a significant shift in the country's pharmaceutical landscape.

This development is likely to lead to increased competition, driving down prices and making these essential medications more accessible to a broader population. However, the high costs associated with these medications have limited their accessibility, particularly for marginalized communities. To address this issue, policymakers must prioritize the strengthening of India's public healthcare system, promote community-based approaches to health and wellness, and address the social determinants of health. By doing so, India may develop a more equitable and sustainable healthcare system that promotes healthy weight management and reduces healthcare disparities. The perspectives of marginalized communities, including those living in rural areas or belonging to lower socioeconomic strata, are critical to developing effective and equitable healthcare solutions. By centering their voices and needs, India may develop more sustainable and inclusive approaches to promoting healthy weight management. Ultimately, India's experience with patent expiry and the subsequent influx of affordable medications has historical parallels with the country's struggles with access to essential medications during the colonial era. By learning from these precedents, India may develop more effective strategies for promoting healthy weight management and reducing healthcare disparities.